News

Brian Donnelly's Appointment as Chief Commercial Officer at Myriad

Brian Donnelly's Appointment as Chief Commercial Officer at Myriad

Myriad Genetics Welcomes Brian Donnelly as CCO

In an exciting development for the healthcare industry, Myriad Genetics, Inc. (NASDAQ: MYGN), renowned for its expertise in molecular diagnostics and precision medicine, has appointed Brian Donnelly as its Chief Commercial Officer (CCO). This pivotal role, effective from May 1, 2025, is expected to significantly influence the company’s trajectory in addressing health through genetic insights.

A Leader with a Proven Track Record

Brian Donnelly is bringing over 20 years of extensive experience in healthcare, diagnostics, and medical technology to Myriad Genetics. His impressive career showcases a wealth of expertise in leading high-performing teams and managing large-scale operations. Donnelly has a reputation for crafting innovative go-to-market strategies that drive substantial growth and facilitate operational excellence.

Sam Raha, the newfound president and CEO of Myriad Genetics, expressed confidence in Donnelly’s abilities, stating, “Brian combines strategic foresight with operational skills and a heartfelt commitment to patient-centric solutions, which make him an invaluable addition to our leadership team.” This sentiment underscores the high expectations placed on Donnelly as he steps into his new role.

Commitment to Healthcare Innovations

Donnelly, eager to embark on this journey with Myriad, articulated his passion for the company’s mission. He emphasized the importance of providing essential genetic information to empower patients, healthcare professionals, and partners alike. His vision includes enhancing the company’s impact while fostering a culture of innovation and growth, ensuring that every decision aligns with advancing health and well-being for all.

Experience with Industry Giants

Before joining Myriad Genetics, Donnelly made notable contributions in senior commercial and management roles at prestigious organizations like Ancestry, Amazon, and Illumina. His previous experiences have equipped him with insights into aligning commercial strategies with broader organizational objectives and have helped enhance brand positioning significantly.

This wealth of knowledge and experience poise him well to support Myriad's objectives to develop innovative molecular tests aimed at assessing disease risks and guiding treatment decisions across diverse medical specialties. His work is expected to lower healthcare costs while simultaneously improving patient outcomes.

About Myriad Genetics

Myriad Genetics stands out as a leader in the realm of molecular diagnostics testing and precision medicine, committed to enhancing health and wellness for the global community. The company is dedicated to creating molecular tests that both assess the risk of diseases and direct treatment options where molecular insights markedly improve patient care.

These advancements contribute not only to better health outcomes but also align with efforts to reduce the associated healthcare expenditures significantly. The overarching goal is clear: empowering healthcare professionals and patients with actionable genetic insights to make informed decisions.

Communication and Outreach Efforts

Myriad Genetics remains dedicated to open communication with its stakeholders. For investor inquiries, the company provides direct contact to Matt Scalo at (801) 584-3532 or via email at IR@myriad.com. Moreover, media inquiries can be directed to Kate Schraml at (224) 875-4493, with the option to reach her at PR@myriad.com. These contact points reflect Myriad's commitment to transparency and engagement.

Frequently Asked Questions

What is the role of Brian Donnelly at Myriad Genetics?

Brian Donnelly has been appointed as the Chief Commercial Officer, responsible for leading the commercial strategy to drive growth and innovation.

What experience does Donnelly bring to Myriad Genetics?

Donnelly brings over 20 years of experience in healthcare and diagnostics, having held senior roles at companies like Ancestry, Amazon, and Illumina.

How does Myriad Genetics impact patient care?

Myriad Genetics develops molecular tests that help assess disease risks and guide treatment decisions, thereby improving patient care significantly.

What is the mission of Myriad Genetics?

Myriad’s mission focuses on advancing health and well-being for all through innovative molecular diagnostics and precision medicine.

How can stakeholders contact Myriad Genetics?

Investors can contact Matt Scalo at (801) 584-3532, while media can reach out to Kate Schraml at (224) 875-4493 for inquiries.

About The Author

About Investors Hangout

Investors Hangout is a leading online stock forum for financial discussion and learning, offering a wide range of free tools and resources. It draws in traders of all levels, who exchange market knowledge, investigate trading tactics, and keep an eye on industry developments in real time. Featuring financial articles, stock message boards, quotes, charts, company profiles, and live news updates. Through cooperative learning and a wealth of informational resources, it helps users from novices creating their first portfolios to experts honing their techniques. Join Investors Hangout today: https://investorshangout.com/

The content of this article is based on factual, publicly available information and does not represent legal, financial, or investment advice. Investors Hangout does not offer financial advice, and the author is not a licensed financial advisor. Consult a qualified advisor before making any financial or investment decisions based on this article. This article should not be considered advice to purchase, sell, or hold any securities or other investments. If any of the material provided here is inaccurate, please contact us for corrections.

Top 10 Most Recent News Articles

FDA Greenlights Halozyme's Cancer Treatment Breakthrough

Updated Category News Views 182

FDA's Seal of Approval: A Game Changer Well, folks, here's a twist in the story of cancer treatment with FDA giving a nod to RYBREVANT FASPRO. Johnson & Johnson's latest offering, fueled by Halozyme's groundbreaking ENHANZE technology, just snagged accelerated approval. We're not just talking any old treatment here; it's a dual-targeted therapy for head and neck cancer...

Continue Reading
ALMIA's Bold Medicare Defense to HHS Committee

Updated Category News Views 112

ALMIA Lays It Out for Medicare Stakeholders The folks at ALMIA are shaking things up, and they're not pulling any punches with the HHS Healthcare Advisory Committee. With this latest move, they've lobbed public comments towards the committee, especially ahead of this intense November 9th meeting. It's part of a larger dialogue kicked off with the Strengthening Medicare...

Continue Reading
Century Lithium's 2026 AGM Time Clarification Issued

Updated Category News Views 89

Time Zone Confusion No More Ah, time zones. They just keep finding ways to trip up the folks at Century Lithium. The company’s got itself in a twist over when the Annual General Meeting's supposed to kick off. Turns out, they've clarified the timing for their 2026 AGM—it’s stamped for 10:00 a.m. Pacific Time. British Columbia’s ditched the seasonal time change, so...

Continue Reading
APP Group's New Conservation Efforts in Sumatra

Updated Category News Views 116

Taking a Bold Step Towards Conservation APP Group, in collaboration with Proforest, WWF-Indonesia, and KKI WARSI, is setting its sights on a more sustainable future with the PROTECT30 initiative. This isn't just another dime-a-dozen CSR project—it’s a concerted effort aimed at conserving Sumatra's precious Bukit Tigapuluh landscape. These folks are playing the long...

Continue Reading
Pigeon Unveils Green Innovations at CIIE 2026

Updated Category News Views 35

An International Celebration: Cultural Connections at CIIE Babies have a way of bringing the world together. Every culture has its own quirks and traditions, but the love for a newborn is common ground. Pigeon gets that, and they're putting it on full display at the China International Import Expo (CIIE) in Shanghai. It's their fourth run at this rodeo, and they’re not...

Continue Reading
ELEGOO Gears Up for Formnext 2026 With New Innovations

Updated Category News Views 139

A New Frontier in 3D Printing The silicon buzz surrounding ELEGOO's unveiling at Formnext 2026 is about as palpable as the smell of hot silicone on a fresh print. This Shenzhen-based company ain't sitting on past laurels. Nope, they're pushing the envelope with a bunch of spiffy new 3D devices, right from FDM printers to the all-in-one M1 Ultra scanner. Spotlight on Key...

Continue Reading
PPL Reports Strong Q3; Long-Term EPS Growth Up

Updated Category News Views 115

Solid Earnings in a Challenging Market Anytime you start hearing a company like PPL boasting about their quarterly earnings, it's time to sit up straight and pay attention. The utility giant didn’t just match expectations, they beat 'em, clocking in with $0.54 per share in ongoing earnings for Q3 2026, up from $0.48 the previous year. Not a bad step forward if you ask...

Continue Reading
TDS Hits Bumps but Keeps Shareholders Happy

Updated Category News Views 48

High Hopes and Hard Hits: TDS in 2026 Listen up, folks. Telephone and Data Systems, Inc. (NYSE: TDS) just popped the hood on their third quarter earnings, and it's a mixed bag with plenty to chew over. Operating revenues are slightly down from last year, but management's got some tricks up their sleeves. CEO Walter Carlson is trumpeting their expanded fiber service...

Continue Reading
Trucordia Expands BYU Sponsorship with Helmet Branding

Updated Category News Views 138

Trucordia Gets Visible with BYU Football Alright, BYU fans and insurance buffs, here's your latest play-by-play. Trucordia, a major player in the insurance game, is ratcheting up its visibility in the college sports scene. They've struck gold with a multiyear sponsorship deal putting their logo on Brigham Young University's (BYU) football helmet bumpers. Talk about a...

Continue Reading
Whimstay's Gambit: Holiday Rentals Savings Game

Updated Category News Views 139

The Bargain Hunt: Last-Minute Savings Whimstay is dangling a carrot for those looking to snag a holiday rental without burning through wads of cash. With the 2026 holiday season barreling down like a freight train, travelers are scouring for deals that won’t sink their budgets. Whimstay's shtick? Enticing discounts for folks who can wrestle with last-minute booking...

Continue Reading

Top 5 Most Recently Viewed Articles

Aspocomp Announces Upcoming Half-Year Report for 2025 Release

Updated Category News Views 175

Aspocomp Set to Release Half-Year Interim Report 2025 Aspocomp Group Plc is gearing up to share its Half-Year Interim Report for the year 2025. Scheduled for release on July 17, 2025, the report will be made available at approximately 9:00 a.m. Finnish time. This publication is highly anticipated by investors and stakeholders keen on the company's performance. Webcast...

Continue Reading
Relief Mental Health Celebrates 2024 Recognition for Excellence

Updated Category News Views 122

Relief Mental Health Celebrates Recognition for Service Excellence Relief Mental Health has proudly been awarded the prestigious BEST of 2024 Award, recognizing its outstanding contributions to mental health services. This award is a significant honor evaluated by BusinessRate, which focuses on verified patient feedback and satisfaction standards. The accolade celebrates...

Continue Reading
Hyundai's Vision: Pioneering the Future of Mobility by 2030

Updated Category News Views 311

Hyundai Motor Company Sets Ambitious Goals for the Future Hyundai Motor Company has laid out a compelling roadmap aimed at achieving 5.55 million global vehicle sales by 2030. This strategic vision showcases the company's commitment to pioneering advancements in the automotive landscape while expanding its electrified portfolio significantly. Electrification at the Core...

Continue Reading
Viasat Finalizes Sale of Energy Services Integration Branch

Updated Category News Views 232

Viasat Finalizes Sale of Energy Services Integration Branch Viasat, Inc. (NASDAQ: VSAT), a prominent player in satellite communications, has successfully completed the sale of its Energy Services System Integration business. This strategic decision comes as part of Viasat’s efforts to refine its operations and focus on areas with greater synergy and growth potential....

Continue Reading
Auxly Cannabis Group Readies for Second Quarter Report Soon

Updated Category News Views 121

Upcoming Earnings Report for Auxly Cannabis Group Inc. Auxly Cannabis Group Inc. is preparing to share its financial results for the second quarter of this year. The results will be announced shortly, providing insights into the company’s performance and strategic direction. Stakeholders and investors are eagerly awaiting this report to gauge the company’s progress in...

Continue Reading